KR102538565B1 - Ｒｓｖ 항바이러스 피라졸로- 및 트리아졸로-피리미딘 화합물 - Google Patents

Ｒｓｖ 항바이러스 피라졸로- 및 트리아졸로-피리미딘 화합물 Download PDF

Info

Publication number
KR102538565B1
KR102538565B1 KR1020177033587A KR20177033587A KR102538565B1 KR 102538565 B1 KR102538565 B1 KR 102538565B1 KR 1020177033587 A KR1020177033587 A KR 1020177033587A KR 20177033587 A KR20177033587 A KR 20177033587A KR 102538565 B1 KR102538565 B1 KR 102538565B1
Authority
KR
South Korea
Prior art keywords
alkyl
mmol
substituted
cycloalkyl
hydroxycarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177033587A
Other languages
English (en)
Korean (ko)
Other versions
KR20170139122A (ko
Inventor
다비드 프란시스 알라인 랑소와즈
제롬 에밀 조르쥬 길레몽
피에르 쟝-마리 베르나르 라보이송
디르크 안드레 에미 로이만스
보리스 로고보이
바딤 빗코
델핀 이본 레이먼드 라르도
앙트완느 벤자민 미체우트
아닐 코울
Original Assignee
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 filed Critical 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니
Publication of KR20170139122A publication Critical patent/KR20170139122A/ko
Application granted granted Critical
Publication of KR102538565B1 publication Critical patent/KR102538565B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177033587A 2015-04-28 2016-04-27 Ｒｓｖ 항바이러스 피라졸로- 및 트리아졸로-피리미딘 화합물 Active KR102538565B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562153753P 2015-04-28 2015-04-28
US62/153,753 2015-04-28
US201562204390P 2015-08-12 2015-08-12
US62/204,390 2015-08-12
PCT/EP2016/059392 WO2016174079A1 (en) 2015-04-28 2016-04-27 Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds

Publications (2)

Publication Number Publication Date
KR20170139122A KR20170139122A (ko) 2017-12-18
KR102538565B1 true KR102538565B1 (ko) 2023-05-30

Family

ID=55860847

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177033587A Active KR102538565B1 (ko) 2015-04-28 2016-04-27 Ｒｓｖ 항바이러스 피라졸로- 및 트리아졸로-피리미딘 화합물

Country Status (29)

Country Link
US (3) US10208048B2 (https=)
EP (1) EP3288942B1 (https=)
JP (1) JP6698693B2 (https=)
KR (1) KR102538565B1 (https=)
CN (1) CN107531715B (https=)
AU (1) AU2016254700B2 (https=)
BR (1) BR112017023263B1 (https=)
CA (1) CA2981404C (https=)
CL (1) CL2017002709A1 (https=)
CY (1) CY1125329T1 (https=)
DK (1) DK3288942T3 (https=)
EA (1) EA035689B1 (https=)
ES (1) ES2905550T3 (https=)
HR (1) HRP20211728T1 (https=)
HU (1) HUE057626T2 (https=)
IL (1) IL254750B (https=)
JO (1) JO3637B1 (https=)
LT (1) LT3288942T (https=)
MA (1) MA41974A (https=)
MX (1) MX369040B (https=)
PH (1) PH12017501958B1 (https=)
PL (1) PL3288942T3 (https=)
PT (1) PT3288942T (https=)
SG (1) SG11201708786SA (https=)
SI (1) SI3288942T1 (https=)
TW (1) TWI703146B (https=)
UA (1) UA120448C2 (https=)
WO (1) WO2016174079A1 (https=)
ZA (1) ZA201707320B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3637B1 (ar) * 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
TW201936193A (zh) * 2017-12-05 2019-09-16 愛爾蘭商健生科學愛爾蘭無限公司 使用組合產品治療ｒｓｖ
SG11202006141RA (en) 2018-01-31 2020-07-29 Janssen Sciences Ireland Unlimited Co Cycloalkyl substituted pyrazolopyrimidines having activity against rsv
US11708369B2 (en) 2018-04-23 2023-07-25 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against RSV
CA3099311A1 (en) * 2018-05-03 2019-11-07 Georgia State University Research Foundation, Inc. Inhibitors of rsv replication and applications thereof
EA202191482A1 (ru) * 2018-11-26 2021-12-14 Янссен Сайенсиз Айрлэнд Анлимитед Компани Другие гетероароматические соединения, обладающие активностью против rsv
JPWO2020138015A1 (ja) 2018-12-27 2021-11-18 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン大環状化合物
EA202193223A1 (ru) 2019-05-23 2022-03-10 Янссен Сайенсиз Айрлэнд Анлимитед Компани Другие гетероароматические соединения, действующие против рсв
CN111440173B (zh) * 2020-03-27 2021-05-14 山东大学 一种pi3k抑制剂的制备方法
WO2022020891A1 (en) * 2020-07-27 2022-02-03 Esfam Biotech Pty Ltd Methods of prophylaxis and treatment of corona virus
WO2022020889A1 (en) * 2020-07-27 2022-02-03 Esfam Biotech Pty Ltd Method of treatment of cytomegalovirus
CA3200111C (en) 2020-10-28 2025-02-18 Shionogi & Co., Ltd. AMIDE DERIVATIVE WITH ANTIVIRAL ACTIVITY
CN117120050A (zh) 2021-02-08 2023-11-24 纽约哥伦比亚大学董事会 用于治疗神经和精神疾病的受氧杂-伊博格碱启发的类似物
CN116425754A (zh) * 2021-12-30 2023-07-14 苏州爱科百发生物医药技术有限公司 芳杂双环化合物及其抗病毒用途
CA3259556A1 (en) * 2022-06-17 2023-12-21 Trawsfynydd Therapeutics, Inc. COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS INFECTION
WO2024121264A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2024121261A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2024121263A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2024121262A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2026003043A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors
WO2026003049A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544625A (ja) 2006-07-20 2009-12-17 メーメット・カーラマン Ｒｈｏキナーゼのベンゾチオフェン阻害剤
WO2011163518A1 (en) 2010-06-24 2011-12-29 Gilead Sciences, Inc. Pyrazolo [1, 5 -a] pyrimidines as antiviral agents

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019483A1 (en) 1994-12-22 1996-06-27 Biochem Pharma Inc. Low molecular weight bicyclic thrombin inhibitors
CA2225255A1 (en) 1995-06-29 1997-01-16 Merck & Co., Inc. Combinations of inhibitors of farnesyl-protein transferase
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5972966A (en) 1996-12-05 1999-10-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6177443B1 (en) 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
KR20020063837A (ko) 1999-07-19 2002-08-05 시오노기세이야쿠가부시키가이샤 아실옥시메톡시카르보닐 측쇄를 갖는 삼환 화합물
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
US20030073681A1 (en) 2001-08-21 2003-04-17 Hauske James R. 2-substituted piperidines that are ligands for monoamine receptors and transporters
US7662826B2 (en) 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
CA2499523C (en) 2002-09-20 2011-04-19 Medisyn Technologies, Inc. Therapeutic agents and corresponding treatments
JP2006504803A (ja) 2002-09-26 2006-02-09 ファイザー・インク ピラゾール誘導体
AU2003275632A1 (en) 2002-10-25 2004-05-13 Mitsubishi Pharma Corporation N-oxide compounds
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
FR2856596B1 (fr) 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
US20070060595A1 (en) 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
US7323567B2 (en) 2003-10-30 2008-01-29 Boehringer Ingelheim (Canada) Ltd. RSV polymerase inhibitors
AR046959A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
NZ551468A (en) 2003-12-24 2010-05-28 Biota Scient Management Polycyclic agents for the treatment of respiratory syncytial virus infections
US8143404B2 (en) 2004-09-13 2012-03-27 Ono Pharmaceutical Co., Ltd Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
WO2007044085A2 (en) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
AU2006260969B2 (en) * 2005-06-20 2011-11-17 Janssen Sciences Ireland Uc 1- ( 2-amino-3- (substituted alkyl)-3H-benzimidazolylmethyl) -3-substituted-1,3-dihydro-benzoimidazol-2-ones with activity on respiratory syncytial virus
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
EP1957476A1 (en) 2005-11-23 2008-08-20 AstraZeneca AB L-alanine derivatives
CA2670083A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
CA2695989A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Certain nitrogen containing bicyclic chemical entities for treating viral infections
US8450343B2 (en) 2007-12-06 2013-05-28 Xianhai Huang Gamma secretase modulators
CN102186479A (zh) 2008-09-10 2011-09-14 凯利普西斯公司 用于治疗疾病的组胺受体的氨基嘧啶抑制剂
AR073920A1 (es) 2008-10-23 2010-12-09 Boehringer Ingelheim Int Derivados urea de nortropanos sustituidos, medicamentos que contienen dichos compuestos , su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa y proceso para su preparacion.
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
KR20100101055A (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동 관련 질환의 치료 또는 예방용 약학적 조성물
AU2010229142A1 (en) 2009-03-23 2011-10-13 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
EA020031B1 (ru) 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2012100342A1 (en) * 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
AU2013249280B2 (en) * 2012-04-17 2017-10-12 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
CA2924527C (en) 2013-09-20 2022-07-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds for treating prostate cancer
US10087151B2 (en) 2014-01-09 2018-10-02 The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
KR101551313B1 (ko) 2014-07-28 2015-09-09 충남대학교산학협력단 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
WO2016071293A2 (en) 2014-11-03 2016-05-12 Iomet Pharma Ltd Pharmaceutical compound
WO2016091774A1 (en) 2014-12-08 2016-06-16 Janssen Sciences Ireland Uc Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv)
CN105777632A (zh) 2015-01-09 2016-07-20 成都贝斯凯瑞生物科技有限公司 芳环并氮杂环衍生物及其应用
JO3637B1 (ar) * 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544625A (ja) 2006-07-20 2009-12-17 メーメット・カーラマン Ｒｈｏキナーゼのベンゾチオフェン阻害剤
WO2011163518A1 (en) 2010-06-24 2011-12-29 Gilead Sciences, Inc. Pyrazolo [1, 5 -a] pyrimidines as antiviral agents
JP2013534524A (ja) 2010-06-24 2013-09-05 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン

Also Published As

Publication number Publication date
HRP20211728T1 (hr) 2022-02-18
CA2981404A1 (en) 2016-11-03
HUE057626T2 (hu) 2022-05-28
IL254750A0 (en) 2017-11-30
LT3288942T (lt) 2021-12-10
DK3288942T3 (da) 2022-01-17
EA201792370A1 (ru) 2018-02-28
US20190248793A1 (en) 2019-08-15
TW201708227A (zh) 2017-03-01
JP6698693B2 (ja) 2020-05-27
KR20170139122A (ko) 2017-12-18
PL3288942T3 (pl) 2022-02-21
PH12017501958A1 (en) 2018-03-26
MA41974A (fr) 2018-03-07
US10611769B2 (en) 2020-04-07
EP3288942A1 (en) 2018-03-07
PH12017501958B1 (en) 2018-03-26
SI3288942T1 (sl) 2022-01-31
MX2017013884A (es) 2018-03-16
US20200223855A1 (en) 2020-07-16
HK1248230A1 (zh) 2018-10-12
MX369040B (es) 2019-10-25
SG11201708786SA (en) 2017-11-29
EP3288942B1 (en) 2021-10-27
IL254750B (en) 2020-07-30
CN107531715A (zh) 2018-01-02
AU2016254700B2 (en) 2020-01-02
EA035689B1 (ru) 2020-07-27
BR112017023263B1 (pt) 2023-04-11
PT3288942T (pt) 2021-12-17
WO2016174079A1 (en) 2016-11-03
BR112017023263A2 (pt) 2018-08-07
ES2905550T3 (es) 2022-04-11
UA120448C2 (uk) 2019-12-10
CL2017002709A1 (es) 2018-04-20
US11084826B2 (en) 2021-08-10
JP2018514544A (ja) 2018-06-07
AU2016254700A1 (en) 2017-10-19
JO3637B1 (ar) 2020-08-27
TWI703146B (zh) 2020-09-01
US10208048B2 (en) 2019-02-19
US20180105529A1 (en) 2018-04-19
CN107531715B (zh) 2021-03-30
CY1125329T1 (el) 2024-02-16
CA2981404C (en) 2023-09-19
ZA201707320B (en) 2020-08-26

Similar Documents

Publication Publication Date Title
KR102538565B1 (ko) Ｒｓｖ 항바이러스 피라졸로- 및 트리아졸로-피리미딘 화합물
JP2023027102A (ja) オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物
JP7305658B2 (ja) 抗ｒｓｖ活性を有するシクロアルキル置換ピラゾロピリミジン
MXPA04007961A (es) Derivados de pirrolopirimidina.
EP3784667B1 (en) Heteroaromatic compounds having activity against rsv
JP2022533429A (ja) Ｒｓｖに対する活性を有する他のヘテロ芳香族化合物
KR20170094180A (ko) 호흡기 세포융합 바이러스 （ｒｓｖ）의 복제에 대하여 저해 활성을 갖는 피페리딘 치환된 삼환식 피라졸로［１，５―ａ］피리미딘 유도체
CA3259558A1 (en) COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS INFECTION
WO2023052593A1 (en) Rsv inhibiting spiro bearing derivatives
TW201410677A (zh) 縮環雜環化合物
HK1248230B (zh) Rsv抗病毒吡唑并-以及三唑并-嘧啶化合物
WO2020138015A1 (ja) ピラゾロ［１，５－ａ］ピリミジン大環状化合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171120

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210401

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230406

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230517

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230525

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230525

End annual number: 3

Start annual number: 1

PG1601 Publication of registration